Suzanne Schindler, MD, PhD, Washington University in St. Louis School of Medicine, St. Louis, MO, discusses the forthcoming adoption of blood-based biomarkers into clinical practice. One of the biggest roadblocks to the use of blood-based biomarkers in clinical care is that insurance companies are currently not paying for them. However, Dr Schindler believes that the demand for patients to be tested and the constraints relating to amyloid-PET and cerebrospinal fluid biomarkers will be so high, that insurers will have to start paying for blood-based biomarkers. Additional constraints to the introduction of blood-based biomarkers include the number of tests which can be performed, the time in which it takes to conduct a test, circulating tests to different parts of the world, and the need for substantial dementia care paradigm adjustments. This interview took place at the Alzheimer’s Association International Conference® (AAIC) 2023 in Amsterdam, Netherlands.
These works are owned by Magdalen Medical Publishing (MMP) and are protected by copyright laws and treaties around the world. All rights are reserved.
